Cover Image

Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism

Abstract The comparative effectiveness and safety of oral anticoagulant therapies to prevent a second recurrent venous thromboembolism (VTE) remains undetermined. We aimed to compare the benefits and harms of direct oral anticoagulant (DOAC) and warfarin therapies in preventing second recurrent VTE...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hye‐Rim Kang (Author), Eric A. Dietrich (Author), Pei‐Lin Huang (Author), Wei‐Hsuan Lo‐Ciganic (Author), Christina E. DeRemer (Author), Haesuk Park (Author)
Format:	Book
Published:	Wiley, 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism
by: Haesuk Park, et al.
Published: (2023)

The current place of direct oral anticoagulants in the prevention/treatment of venous thromboembolism
by: Tomić Maja
Published: (2020)

New anticoagulants for the prevention of venous thromboembolism
by: Cecilia Becattini, et al.
Published: (2010)

Anticoagulant therapy for acute venous thromboembolism
by: Hilal Ermiş, et al.
Published: (2017)

The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment
by: К. V. Lobastov, et al.
Published: (2020)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
by: Maha Al-Ghafry, et al.
Published: (2022)

CURRENT TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS WITH ANTICOAGULANTS: APIXABAN
by: I. S. Yavelov
Published: (2015)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
by: Ke-Xin Sun, et al.
Published: (2021)

Underutilization of Anticoagulant for Venous Thromboembolism Prophylaxis in Three Hospitals in Jakarta
by: T. Djumhana Atmakusuma, et al.
Published: (2016)

Assessment of direct-acting oral anticoagulants for the treatment of venous thromboembolism in cancer patients in Thai Tertiary Care Hospital
by: Jennis Meanwatthana, et al.
Published: (2022)

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
by: Emilie Clay, et al.
Published: (2018)

Direct Oral Anticoagulant (DOAC) to Warfarin Transitions in a Pharmacist-led Anticoagulation Clinic
by: Ashley G. Woodhouse, et al.
Published: (2019)

EFFICACY AND SAFETY OF THE ORAL ANTICOAGULANTS IN THE MANAGEMENT OF VENOUS THROMBOEMBOLISM: INDIRECT COMPARISON
by: V. I. Petrov, et al.
Published: (2016)

Is there still room for warfarin after the appearance of direct oral anticoagulants?
by: E. P. Panchenko
Published: (2023)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
by: Hallinen T, et al.
Published: (2021)

New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism
by: Wumaier K, et al.
Published: (2022)

Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism
by: A. V. Rudakova
Published: (2015)

Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism
by: A. V. Rudakova
Published: (2015)

Risk of recurrent stroke for Asian stroke patients treated with non-vitamin K antagonist oral anticoagulant and warfarin
by: Sheng-Feng Lin, et al.
Published: (2020)

A Cross-sectional Study of the Assessment of Venous Thromboembolism Risk and Use of Anticoagulant Thromboprophylaxis
by: Emile Abimana, et al.
Published: (2022)

New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients
by: Gerotziafas GT, et al.
Published: (2014)

Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis
by: V. I. Petrov, et al.
Published: (2017)

Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis
by: V. I. Petrov, et al.
Published: (2016)

Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients
by: Lee YJ
Published: (2014)

Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis
by: V. I. Petrov, et al.
Published: (2017)

CONSIDERING QUESTION OF SAFETY OF DIRECT ORAL ANTICOAGULANTS: THE RESULTS OF THE COMPARISON OF APIXABAN AND WARFARIN
by: Igor S. Yavelov
Published: (2018)

Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study
by: Shuyi Wu, et al.
Published: (2024)

CLINICAL DISCUSSION OF A PATIENT WITH RECURRENT VENOUS THROMBOEMBOLIC COMPLICATIONS
by: A. L. KOMAROV
Published: (2017)

Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation
by: Caroline Brais, et al.
Published: (2017)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017)

The New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy
by: Taki Galanis, MD, et al.
Published: (2014)

Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism
by: Maodi Xu, et al.
Published: (2018)

Oral anticoagulants for the treatment of venous thromboembolism and non-valvular atrial fibrillation: a cost analysis
by: Isabella C DENARDIN, et al.
Published: (2021)

WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY
by: N. A. Novikova, et al.
Published: (2016)

Impact of an ambulatory care pharmacist on provider relative value units in a rural clinic
by: Christina E. DeRemer, et al.
Published: (2022)

Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China
by: Yue Wu, et al.
Published: (2024)

Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
by: Abdel-Razeq H, et al.
Published: (2011)

Recent advances in mechanism and anticoagulant therapy of venous thromboembolism in patients with non-dialysis chronic kidney disease
by: Jia-xin Wang, et al.
Published: (2024)

Safety of discontinuation of anticoagulants after venous thromboembolism: whether D-dimer level should be taken into account?
by: I. S. Yavelov
Published: (2023)